Osteoarthritis as an interdisciplinary problem: treatment algorithm for physicians and general practitioners
https://doi.org/10.14412/1996-7012-2021-5-68-75
Abstract
Modern therapy of osteoarthritis (OA) consists of four sequential stages and includes non-pharmacological, pharmacological and surgical methods of treatment, and also assumes the possibility of collaborative management of the patient by doctors of different specialties, which allows to optimize the processes of diagnosis and treatment. The article presents simple and convenient algorithms, including diagnostic criteria, options for providing medical care, as well as situations (so-called red flags) that require referral of a patient to a specialist, primarily a rheumatologist. It has been demonstrated that the early use of the well-proven SYSADOA in any localization of OA, in particular the combined drugs of chondroitin sulfate and glucosamine, can increase the effectiveness of treatment, reduce possible functional disorders, and minimize the adverse effects of analgesic therapy.
About the Authors
A. M. Lila
V.A. Nasonova Research Institute of Rheumatology; Department of Rheumatology, Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
2/1, Barrikadnaya Street, Build. 1, Moscow 125993
L. I. Alekseeva
V.A. Nasonova Research Institute of Rheumatology; Department of Rheumatology, Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
2/1, Barrikadnaya Street, Build. 1, Moscow 125993
E. A. Taskina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
N. G. Kashevarova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Balabanova RM, Dubinina TV. Five-year (2013–2017) trends in the incidence and prevalence of musculoskeletal system diseases among the adult population of Russia. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2019;13(4):11-7. (In Russ.). doi: 10.14412/1996-7012-2019-4-11-17.
2. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) results. 2020. http://ghdx.healthdata.org/gbdresults-tool.
3. Hunter DJ, March L, Chew M. Osteoarthritis in 2020 and beyond: a Lancet Commission. Lancet. 2020 Nov 28; 396(10264):1711-2. doi: 10.1016/S0140-6736(20)32230-3. Epub 2020 Nov 4.
4. Veronese N, Cereda E, Maggi S, et al. Osteoarthritis and mortality: A prospective cohort study and systematic review with meta-analysis. Semin Arthritis Rheum. 2016 Oct;46(2):160-7. doi: 10.1016/j.semarthrit.2016.04.002.
5. Constantino de Campos G, Mundi R, Whittington C, et al. Osteoarthritis, mobilityrelated comorbidities and mortality: an overview of meta-analyses. Ther Adv Musculoskelet Dis. 2020 Dec 25;12: 1759720X20981219. doi: 10.1177/1759720X20981219. eCollection 2020.
6. Lila AM, Alekseeva LI, Taskina EA. Modern approaches to the treatment of osteoarthritis, taking into account updated international recommendations. Russkii meditsinskii zhurnal. 2019;3(11-2):48-52. (In Russ.).
7. Coimbra IB, Plapler PG, de Campos GC. Generating evidence and understanding the treatment of osteoarthritis in Brazil: a study through Delphi methodology. Clinics (Sao Paulo). 2019 May 13;74:e722. doi: 10.6061/clinics/2019/e722.
8. Martel-Pelletier J, Maheu E, Pelletier JP, et al. A new decision tree for diagnosis of osteoarthritis in primary care: international consensus of experts. Aging Clin Exp Res. 2019 Jan;31(1):19-30. doi: 10.1007/s40520-018-1077-8. Epub 2018 Dec 11.
9. Block JA, Cherny D. Management of Knee Osteoarthritis: What Internists Need to Know. Med Clin North Am. 2021 Mar;105(2): 367-85. doi: 10.1016/j.mcna.2020.10.005.
10. Klinicheskie rekomendatsii «Osteoartroz» [Clinical guidelines «Osteoarthritis»]. Moscow: Obshcherossiiskaya obshchestvennaya organizatsiya «Assotsiatsiya revmatologov Rossii»; 2016. https://pharmspb.ru/docs/lit/Revmatologia
11. Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2017. 464 p.
12. Bruyere O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019 Apr 30. pii: S0049–0172(19)30043–5. doi: 10.1016/j.semarthrit.2019.04.008.
13. Pradelli L, Sinigaglia T, Migliore A, et al. Non-Surgical Treatment of Knee Osteoarthritis: Multidisciplinary Italian Consensus on Best Practice. Ther Clin Risk Manag. 2021 May 28;17: 507-30. doi: 10.2147/TCRM.S288196. eCollection 2021.
14. The Royal Australian College of General Practitioners. Guideline for the Management of Knee and Hip Osteoarthritis. 2nd ed. East Melbourne: RACGP; 2018. 71 p.
15. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014 Mar;22(3): 363-88. doi: 10.1016/j.joca.2014.01.003.Epub 2014 Jan 24.
16. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020 Feb;72(2):149-62. doi: 10.1002/acr.24131. Epub 2020 Jan 6.
17. Alekseeva LI, Taskina EA, Kashevarova NG. Osteoarthritis: epidemiology, classification, risk factors, and progression, clinical presentation, diagnosis, and treatment. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2019;13(2):9-21. (In Russ.). doi: 10.14412/1996-7012-2019-2-9-21
18. Kashevarova NG, Alekseeva LI, Taskina EA, Smirnov AV. The leading factors of the progression of osteoarthritis of the knee joints. the effect of symptomatic delayed-acting drugs on the course of the disease (a 5-year prospective study). Farmateka. 2017;(7):40-5. (In Russ.).
19. Martel-Pelletier J, Roubille C, Abram F, et al. First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. Ann Rheum Dis. 2015 Mar;74(3):547-56. doi: 10.1136/annrheumdis-2013- 203906.Epub 2013 Dec 13.
20. Raynauld JP, Pelletier JP, Abram F, et al. Long-term effects of glucosamine and chondroitin sulfate on the progression of structural changes in knee osteoarthritis: six-year follow-up data from the osteoarthritis initiative. Arthritis Care Res (Hoboken). 2016 Oct; 68(10):1560-6. doi: 10.1002/acr.22866.Epub 2016 Sep 16.
21. Yang W, Sun C, He SQ, et al. The Efficacy and Safety of Disease- Modifying Osteoarthritis Drugs for Knee and Hip Osteoarthritis – a Systematic Review and Network Meta-Analysis. J Gen Intern Med. 2021 Jul;36(7):2085-2093. doi: 10.1007/s11606-021-06755-z. Epub 2021 Apr 12.
22. Singh JA, Noorbaloochi S, MacDonald R, Maxwell LJ. Chondroitin for osteoarthritis. Cochrane Database Syst Rev. 2015 Jan 28;1: CD005614. doi: 10.1002/14651858.CD005614.pub2.
23. Zhu X, Sang L, Wu D, et al. Effectiveness and safety of glucosamine and chondroitin for the treatment of osteoarthritis: a meta-analysis of randomized controlled trials. J Orthop Surg Res. 2018 Jul 6;13(1):170. doi: 10.1186/s13018-018-0871-5.
24. Alekseeva LI. Combined drugs in the treatment of osteoarthritis. The effectiveness of teraflex. Meditsinskii Sovet. 2013;(4):100-5. (In Russ.).
25. Badokin VV. Synergistic and additive effects of chondroitin sulfate and glucosamine in the stimulation of cartilage in osteoarthritis. Effektivnaya farmakoterapiya. 2013;(38): 68-75. (In Russ.).
26. Rebrov AP, Romanova IA, Gaidukova IZ. Cardiovascular safety and efficacy of the combined symptomatic slow-acting drug glucosamine and chondroitin sulfate in patients with gonarthrosis. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2016;10(2) 37-42. (In Russ.). doi: 10.14412/1996-7012- 2016-2-37-42
27. Benevolenskaya LI, Alekseeva LI, Zaitseva EM. Efficacy of teraflex in patients with osteoarthritis of the knee and hip joints (open randomized study). Russkii meditsinskii zhurnal.2005;(8):525-7. (In Russ.).
28. Lila AM, Mazurov VI, Shidlovskaya OV, Shostak MS. Teraflex in the complex therapy of knee osteoarthritis and spinal osteochondrosis (results of a clinical study). Russkii meditsinskii zhurnal. 2005;13(24):1618-22.(In Russ.).
29. Alekseeva LI, Kashevarova NG, Sharapova EP, et al. Comparison of continuous and intermittent treatment of patients with osteoarthritis of the knee joints with the combined drug Teraflex. Nauchno-prakticheskaya revmatologiya. 2008;(3);68-72. (In Russ.).
30. Lila AM, Alekseeva LI, Telyshev KA, et al. The efficiency of treatment with a combined chondroitin sulfate and glucosamine hydrochloride drug for knee and hip osteoarthritis: intermediate results of a Russian observational study. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2020;14(3):71-8. (In Russ.). doi: 10.14412/1996-7012-2020-3-71-78
31. Honvo G, Reginster JY, Rabenda V, et al. Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs Aging. 2019 Apr;36(Suppl 1):65-99. doi: 10.1007/s40266-019-00662-z.
32. Lila AM, Alekseeva LI, Babaeva AR, et al. Pharmacological treatment options for osteoarthritis: focus on symptomatic slowacting drugs for osteoarthritis (SYSADOA) and individual patient characteristics: Resolution of the International Expert Meeting. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2019;13(4): 143-7. (In Russ.). doi: 10.14412/1996-7012-2019-4-143-147
Review
For citations:
Lila AM, Alekseeva LI, Taskina EA, Kashevarova NG. Osteoarthritis as an interdisciplinary problem: treatment algorithm for physicians and general practitioners. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2021;15(5):68-75. (In Russ.) https://doi.org/10.14412/1996-7012-2021-5-68-75
Views:
1254
Email this article 